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Abstract
Systemic lupus erythematosus (SLE) is a clinically heterogeneous, humoral autoimmune disorder. The unifying feature
among SLE patients is the production of large quantities of autoantibodies. Serum samples from 129 patients collected
before the onset of SLE and while in the United States military were evaluated for early pre-clinical serologic events. The first
available positive serum sample frequently already contained multiple autoantibody specificities (65%). However, in 34 SLE
patients the earliest pre-clinical serum sample positive for any detectable common autoantibody bound only a single
autoantigen, most commonly 60 kD Ro (29%), nRNP A (24%), anti-phospholipids (18%) or rheumatoid factor (15%). We
identified several recurrent patterns of autoantibody onset using these pre-diagnostic samples. In the serum samples
available, anti-nRNP A appeared before or simultaneously with anti-nRNP 70 K in 96% of the patients who had both
autoantibodies at diagnosis. Anti-60 kD Ro antibodies appeared before or simultaneously with anti-La (98%) or anti-52 kD
Ro (95%). The autoantibody response in SLE patients begins simply, often binding a single specific autoantigen years before
disease onset, followed by epitope spreading to additional autoantigenic specificities that are accrued in recurring patterns.
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Introduction
High concentrations of autoantibodies are found in sera from
nearly all patients with systemic lupus erythematosus (SLE), a
heterogenous autoimmune disorder, and are important in many
SLE clinical sequelae [1,2]. These autoantibodies are frequently
directed against dsDNA with associated nucleosome components,
as well as common RNA-proteins such as Sm, nRNP, Ro, and La.
Anti-dsDNA antibodies are found in about 50% of the sera from
untreated lupus patients and are sufficiently specific for lupus that
they contribute to the accepted SLE classification criteria [3,4].
These antibodies are often associated with lupus renal disease
[5–7]. Recent work has suggested that treatment of lupus with
corticosteroids upon detection of rising dsDNA antibody titers and
complement split products can oftentimes avert more serious
clinical involvement [8]. Chromatin, histones and other nucleo-
some components are also commonly targeted by autoantibodies
in SLE patient sera [9]. Approximately 25% of SLE patients
produce antibodies against the Sm proteins of the spliceosome,
particularly autoantibodies to the B/B’ proteins [10,11]. The
related anti-nRNP antibodies, directed against nRNP 70 K,
nRNP A, and nRNP C, are more prevalent but less specific for
SLE [12]. Antibodies against the Ro autoantigen are present in
approximately 50% sera from SLE patients [13], though even less
specific, and generally bind a 60 kD Ro protein with many also
binding a 52 kD Ro moiety.
Recent data suggest that lupus autoantibodies do not arise
simultaneously, but rather develop sequentially over time [14,15].
If true, then the first SLE specific autoantibody specificity
establishes lupus humoral autoimmunity and may well be the
conduit through which the formation of all subsequent lupus-
related autoantibodies are generated, thus making the identifica-
tion of the first lupus autoantigen bound critical to understanding
lupus immune pathogenesis. Once initiated, epitope spreading
provides a mechanism for the development of autoimmunity in
SLE patients [16–22]. The anti-Sm autoantibody system, for
example, progresses from a single initial epitope to a complex mix
of multiple specificities revealing an active autoimmune develop-
mental process [16–19]. Similarly, the anti-60 kD Ro response
begins from a single epitope and develops into a complex multi-
epitope response [20–22].
While much effort has focused on identifying pathogenic
mechanisms of these autoimmune responses, the early events in
human SLE pathogenesis remain poorly understood. Patients are
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autoantibody production has commenced. Data are consequently
sparse from the pre-diagnostic interval in human SLE develop-
ment [14,23–26]. Prospective serum collections such as the U.S.
Department of Defense Serum Repository (DoDSR) provide
access to serum samples which contain the cumulative immune
histories of subsequent SLE patients, thus offering a unique
opportunity to evaluate the immune system before clinical illness
onset [14,23–26]. We have found that autoantibodies consistently
appear years before diagnosis of SLE within this cohort of patients
[14]; however, we have not previously defined the historical order
of protein-specific autoantibody appearance with the purpose
being to identify the autoantibodies that first bind lupus
autoantigens.
Thus, we sought to identify the first disease-associated auto-
antibody specificities that initiate autoimmunity in the process that
culminates in SLE as a clinical illness. The earliest autoantibodies
that develop in patients destined to develop SLE should be
involved in the transition from normal immune regulation to
autoimmune dysregulation and are therefore critically important
components of the mechanisms of lupus pathogenesis. We show
that the set of initiating autoantibodies is usually limited to Ro,
nRNP A, phospholipids and rheumatoid factor of the specificities
tested, suggesting that there appears to be an autoantigentic
bottleneck that restricts autoantibody initiation to a relatively small
number of initial antigenic structures on the pathway to SLE
development.
Results
Prevalence and Time of Appearance of Autoantibodies
before Diagnosis
Initial solid-phase autoantibody testing was performed by a
commercial assay (Bio-Rad BioPlex ANA 2200, Hercules, CA) on
600 serum samples from 129 SLE patients and another 199 serum
samples from 129 matched controls. These data were supple-
mented by Western blot analysis of 434 sera from 118 of the SLE
patients. All of the results are from, and restricted to, sera within
the normal range of Factor XIIIb.
Of the 129 patients, 114 (88%) had detectable autoantibodies
beforeSLE diagnosis.The most commonantigenrecognized before
diagnosis was 60 kD Ro; 63 (49%) bound 601 kD Ro before 4 SLE
criteriawerepresent(Table 1).Antibodiesto60 kDRoappearedan
average of 3.54 years (median 3.12) before diagnosis, which was one
of the earliest of specificities to appear relative to the time of SLE
diagnosis (Figure 1). Anti-centromere B developed early but was
only found in 5 (,5%) of the SLE patients and were usually only
present transiently. Anti-60 kD Ro antibodies were more common
Figure 1. Autoantibodies precede lupus classification and
occur in linked subsets. Kaplan-Maier survival curves for the onset
of each autoantibody specific as measured by a solid phase, bead-
based assay are presented. Anti-60 kD Ro, anti-La and anti-52 kD Ro are
among the earliest specificities detected by this method. In contrast,
anti-68 kD nRNP and nRNP A specificities are frequently detected closer
to the time of lupus classification.
doi:10.1371/journal.pone.0009599.g001
Table 1. Prevalence and time of onset of autoantibodies as detected by the BioPlex 2200 ANA Screen kit and demographics of
patients positive for each autoantibody.
Number Positive Time of Onset
Ever Before Mean Median
Diagnosis % female % male %EA %AA
% (n) % (n) Yrs prior to diagnosis (n=84) (n=45) (n=34) (n=80)
60 kD Ro 56 (72) 48 (63) 3.54 3.12 58 51 29 66*
La 36 (47) 30 (39) 3.05 2.42 37 36 24 41
52 kD Ro 36 (46) 29 (38) 2.49 2.26 42 24 26 43
nRNP A 50 (65) 42 (54) 1.85 1.71 52 47 32 63*
P 30 (39) 26 (33) 1.61 0.67 27 36 15 38
Sm 51 (66) 44 (57) 1.54 0.94 48 58 32 61*
dsDNA 42 (54) 33 (42) 1.26 0.53 40 44 32 45
chromatin 57 (73) 47 (61) 1.24 1.61 54 62 47 63
nRNP 70 K 19 (24) 14 (18) 0.68 0.61 21 13 21 20
Antibodies to nRNP A, Sm, and 60 kD Ro are significantly more common in African-Americans.
EA= European-Americans.
AA=African-Americans.
*p,0.008.
doi:10.1371/journal.pone.0009599.t001
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in this Military population (OR=5.1; p=0.0007) (Table 1).
Before diagnosis the prevalence of antibodies to chromatin
(47%), Sm (44%), and nRNP A (42%) were similar to anti-60 kD
Ro (49%). The first appearance of these specificities was more
proximal to diagnosis with the mean onset of anti-chromatin (1.24
years before diagnosis), anti-Sm (1.54 years) and anti-nRNP A
(1.85 years), occurring approximately half as close to classification
as the average interval for anti-60 kD Ro (Figure 1). Anti-Sm and
anti-nRNP A were also significantly more common in African-
American patient sera relative to European-Americans (OR=3.3
and OR=3.5 respectively; p,0.008) (Table 1), supporting
previously published studies [14,15].
Twelve controls had autoantibodies detected using the com-
mercial bead-based, solid phase assay. One control had antibodies
to nRNP A, nRNP 70 K and chromatin that were present in both
early and late samples. Sm, nRNP A, and centromere B were each
bound by one control and these autoantibodies were detected in
both an early and a late sample. Three controls had antibodies
against dsDNA, two controls had antibodies against La, and one
control had antibodies against ribosomal P; however, all six of
these controls had an additional subsequent sample tested that was
negative.
Prior to diagnosis, autoantibodies were detected by at least one
of the commercial bead-based, solid phase assays in 88% of
patients. Meanwhile anti-nuclear (ANA) immunofluorescent assays
also detected autoantibodies in an overlapping but not identical
88% of these same pre-diagnostic SLE samples. Indeed, only 6
individuals were negative for ANA by both methods. Interestingly,
in patients with a sample within the two years prior to diagnosis
(n=105), 86% had detectable levels of autoantibodies using the
commercial bead-based assays, while 82% had autoantibodies
detected using ANA immunofluorescence.
The Earliest Autoantigen Target Was Identified for a
Subset of Patients
Using the solid phase assay, we had 37 patients with only one
detectable autoantibody specificity in their first available antibody
positive sample; however, 3 patients had only anti-La detected but
these 3 patients were additionally positive for anti-60 kD Ro by
Western blot analysis. Thus, these 3 patients were considered to
have multiple specificities in their first available sample and were
included in the multiple specificity group for analysis. The
remaining 34 patients had no additional specificities identified
by Western blot analysis in the serum sample positive by solid
phase assay.
Of the 34 patients with a single initial specificity, 10 (29%) had
detectable antibodies against 60 kD Ro, 8 (24%) to nRNP A, 6
(17%) to phospholipids and 5 (15%) had rheumatoid factor (IgG
and/or IgM) as the initial sole lupus autoantibody detected.
Unexpectedly, no patient had anti-nRNP 70 K or anti-Sm as the
first sole detectable autoantibody. Antibodies to ribosomal P was
found in one individual and antibodies to either dsDNA or C1q
were found in two individuals each (Figure 2A, 2B). The final
autoantibody profile in these 34 patients with an initial single
autoantibody shows the development of antibodies against
additional specificities in the majority of patients (68%) (Figure 2C).
Lupus Autoantibodies May Be Initially Absent in
Prediagnostic SLE Sera
Using the antigen-specific responses measured by luminex bead
based assays, we had 25 patients for which at least one serum
sample was negative and subsequent serum samples were positive
for lupus-specific autoantibodies in the commercial assay.
Nineteen patients had multiple autoantibodies and six patients
had a single autoantibody in their first reactive serum sample. Five
of the 6 patients with one initial specificity proceeded to develop
multiple autoantibodies before meeting SLE classification criteria;
therefore, a total of 24 of these 25 patients had multiple auto-
antibodies present before diagnosis. The time between the last
negative and first positive sample was 1.32 years (median=1.26
years) in the patients who had one autoantibody and 2.9 years
(median=3.35 years) in the patients who had multiple autoanti-
bodies (p=0.027). No significant differences in gender, race, or
age at diagnosis were found between the patients with a single
initial autoantibody and those with multiple specificities.
The antigens targeted in the initial positive sample of the 25
patients who developed autoantibodies under observation are
largely (89.5%) detectable in the subsequent autoantibody profile.
Of the 129 SLE patients, 84 had multiple autoantibody
specificities detectable in their first autoantibody positive serum
sample. The early autoantibodies discovered by analysis of these
individuals with negative samples followed by sole specificities
were also among the specificities recognized by samples from
individuals with multiple autoantibodies present in the first
available sample.
Accumulation of Antibodies within Linked Systems
Follows Distinct Patterns
When analyzing all patients in this study, 63 had antibodies to
nRNP A at some time during the pre-diagnostic period. Of these
63 patients, 24 also had antibodies to nRNP 70 K while the other
39 had no detectable anti-nRNP 70 K at any tested time point.
Thirteen of the 24 patients had antibodies to both nRNP 70 K
and nRNP A that were detected simultaneously, in the same
serum sample. Antibodies to nRNP A preceded antibodies to
nRNP 70 K in 10 patients, while antibodies to nRNP 70 K
preceded antibodies to nRNP A in only 1 patient (Figure 3A).
When all available cases are considered, 11 cases allow us to
discriminate between the appearance of anti-nRNP A from anti-
nRNP 70 K (Figure 3A) with anti-nRNP A appearing before anti-
70 K in 10 and the reverse in only one of the 11 individuals with
informative sera (OR=10, p=0.002). This observation is
consistent with the possibility of a sampling issue in a substantial
proportion of the 19 with multiple specificities in the earliest
positive serum. Under this scenario a serum sample would not
have been collected during the time that a single initiating
autoantibody would have been present.
A subset of these samples was studied by Western blotting
against HeLa cell extract. The samples selected had anti-nRNP
70 K and anti-nRNP A first together (17 samples in the solid
phase assays) along with those in which anti-nRNP A was detected
first alone (25 samples by solid phase assay). Western blots
confirmed the findings that no patient had anti-nRNP 70 K
antibodies as an initiating autoantibody alone and that in no
instance did anti-nRNP 70 K appear before anti-nRNP A by
Western blot (data not presented).
Of the total collection tested, 59 patients had antibodies against
Sm and nRNP A (detected by solid phase or Western blot) while 8
had anti-nRNP A without anti-Sm and 7 had anti-Sm without
anti-nRNP A. Of the 59 patients who had both anti-Sm and anti-
nRNP A, 43 had both specificities in the same sample. Antibodies
to nRNP A appeared before antibodies to Sm in 9 patients and
anti-Sm appeared before anti-nRNP A in 7 patients (X
2=0.250,
p=0.617) (Figure 3B).
Antibodies against La were found in a subset of those with anti-
60 kD Ro. Antibodies to both 60 kD Ro and La were found in 51
The Initiation of Human SLE
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9599Figure 2. Initial autoantibody targets in the pre-diagnosis cohort. (A) The front (black) bars show the number of patients developing
antibodies to respective antigen as their initial single autoantibody specificity. The middle (dark gray) bars show the number of patients with
antibodies to the respective antigen in their first positive sample, which includes individuals who had multiple autoantibody specificities in their
earliest positive serum. The back (light gray) bars show the total number of patients ever positive for each specificity. (B) Initial autoantibody profiles
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in 37 of these 51 patients (Figure 3C). In 14 of these 51 patients
anti-60 kD Ro antibodies appeared prior to anti-La. In addition,
anti-La antibodies did not appear before anti-60 kD Ro antibodies
in any case that eventually developed both autoantibody
specificities. Overall, we can discriminate the earlier appearance
of anti-60 kD Ro in 14 patients while anti-La did not appear
earlier in patients developing both specificities (OR =14.0,
p=0.0002) (Figure 3C).
Antibodies to both dsDNA and chromatin were present in 48
patients; anti-chromatin without anti-dsDNA was present in 26
patients and anti-dsDNA without anti-chromatin was seen in only 7
patients (Figure 3D). Of the 48 patients who had both antibodies
present, 15 had anti-chromatin preceding anti-dsDNA, while 9 had
anti-dsDNA preceding anti-chromatin. Twenty-four patients had
antibodies to dsDNA and chromatin that appeared in the same
serum sample. Overall, 15 patients had anti-chromatin first and 9
patients had anti-dsDNA first (X
2=1.5, p=0.22) (Figure 3D).
Appearance of Autoantiboides Detected by a
Bead-Based Assay Compared to Traditional Assays
The sera used in this study have previously been tested for
autoantibodies using the traditional assays used by clinical
laboratories, as described in previous publications [14,23–26].
The data obtained using this solid-phase, bead-based assay were
compared to these assays for autoantibodies time of appearance.In
this collection there were 69 cases where the sera available
discriminate between the earlier appearance of a positive
antinuclear antibody (ANA) or a lupus-specific autoantibody. In
22 cases, the immunofluorescent ANA was detected first, while in
47 a specific autoantibody appeared first. Antibodies to common
lupus antigens as detected by this solid-phase, bead-based assays
were detectable prior to antibodies against cardiolipin (APL),
Rheumatoid Factor (RF), and C1q in the majority of patients in
which both were present (n=79, n=98, and n=85, respectively).
However, some patients developed antibodies to APL (6 patients),
RF (5 patients), and C1q (2 patients) before antibodies to the other
autoantigens tested were detectable.
The ANA test results constitute a special situation where
something on the order of 10,000 antigens are tested simulta-
neously, including the 12 specific autoantigens being reported
herein. The ANA was positive along with one of the 12 specific
autoantigens individually tested in 14 of the first positive serum
from the 34 subjects with a single specificity. In two of these the
ANA was positive in an earlier serum (from the five of these 34
who had an earlier serum available). This result suggests that some
additional autoantigens may be important in lupus serological
progression beyond those tested. While single autoimmunity
initiating specificities cannot be concluded for these subjects, a
positive ANA, without other specific autoantibodies detected, is
not inconsistent with this possibility.
Discussion
Lupus disease expression is derived from the consequences of
humoral autoimmunity. We show that lupus-specific autoimmu-
nity evolves from a limited set of autoantigens, with most of the
initiating autoantibodies being anti-60 kD Ro, anti-nRNP A, aPL
or RF, but unexpectedly apparently anti-Sm and anti-nRNP 70 K
being excluded as specificities that initiate lupus autoimmunity
alone. This conclusion is bounded by the time between the
forming autoantibody against initating autoimmune specificity and
the second specificity. Because sera collected from each subject
were separated by months to years, it is possible that if a second
specificity follows the first rapidly, by day to weeks, then we would
detect dual specificities appearing together in the collection studied
herein. This is a formal possibility for anti-nRNP A and anti-
nRNP 70 K and for the anti-60 kD Ro and anti-La, among
others, though parsimony and the data showing that autoanti-
bodies can first form against nRNP A and 60 kD Ro argue against
this possibility.
The initiating autoantibodies are, at the point first detected, the
earliest evidence in the patient of a lupus-specific autoimmune
process. That they are a small subset of the known lupus-specific
autoantibodies suggest that the number of structures through
which human lupus is initiated is very restricted. This is the lupus
autoantigenic bottleneck through which the autoimmune process
must past to culminate in clinical inflammatory illness. If the
subsequent extraordinary complexity of lupus-specific humoral
Figure 3. The order of onset of protein-specific autoantibodies
within the linked systems. Antibodies to nRNP A commonly
appeared prior to anti-70 K (A) while a variable onset was seen
between Sm and nRNP A (B). Anti-60 kD antibodies virtually always
precede anti-La antibodies (C). The order of appearance did not favor
anti-dsDNA or anti-chromatin when compared to each other (D).
doi:10.1371/journal.pone.0009599.g003
detected in 34 patients with a single initial specificity and (C) the final autoantibody profile for the patients with a later sample available. Colorimetric
changes represent autoantibody concentration, ranging from green showing lower reactivity to bright red for high binding.
doi:10.1371/journal.pone.0009599.g002
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nings, then epitope spreading, as previously shown in animal
models [16,18,20–22] and in man [17,18,20], is a critical process
for lupus autoimmune development and maturation. At the
moment there is no evidence supporting the alternative hypothesis
that new lupus specificities arise de novo, independent of and
uninfluenced by the lupus autoimmune specificities that precede
them.
Indeed, epitope spreading appears to follow some limited
pathways that are evident from the data available herein. Anti-60
kD Ro precedes anti-La and anti-52 kD Ro in those subjects who
eventually develop two or three of these autoantibodies. Anti-
nRNP A precedes anti-nRNP 70 kD and anti-nRNP C, following
an analogous pattern of developing complexity. Meanwhile,
the temporal relationships between anti-Sm and ant-nRNP A
and between anti-dsDNA and anti-chromatin do not show a
dominating temporal relationship (Figure 3).
The most extensive previous studies of autoantibody develop-
ment were performed using sera from a large cohort of connective
tissue disease patients. Concentrating on patients already diag-
nosed with a systemic autoimmune rheumatic disease (many with
mixed connective tissue disease) Greidinger and Hoffman [15]
found that the spliceosomal autoimmune responses frequently
began by targeting the nRNP 70 K protein followed by Sm B’.
Anti-nRNP A and anti-nRNP C developed later, while antibodies
to Sm D1 developed as the last of all the common snRNPs. Ro,
La, dsDNA, chromatin or ribosomal P autoantibodies were not
evaluated [15]. The most obvious explanation for the differences
between their identification of anti-nRNP 70 K as an initiating
autoantibody and our identification of anti-nRNP A is that their
collection was enriched for mixed connective tissue disease.
Meanwhile, this report strictly concerns lupus. The initiating
autoantigen could easily be a disease distinguishing feature in
disease pathogenesis.
Existing evidence supports a model for anti-Ro (in those patients
who do not also develop anti-La) [20] involving Epstein-Barr virus
Nuclear Antigen-1 (EBNA-1) as the cross-reacting hetero-antigen
that mediates the antibody cross-reaction making 60 kD Ro an
initiating lupus autoantigen [20]. Anti-Sm B autoantibodies are
initiated through PPPGMRPP [17,18,27], which is repeated
exactly or nearly exactly four times in the carboxy-terminus of
Sm B. But the results herein do not show that Sm is an initiating
autoantigen for lupus. Both nRNP A with PPPGMIPP and nRNP
C with PAPGMRPP have epitopes that cross-react with anti-
PPPGMRPP autoantibodies [28–30].
EBNA-1 appears to be the primordial hetero-antigen with anti-
PPPGRRP of EBNA-1 cross-reacting in a way that transforms the
hetero-immune response into an autoimmune response [31,32].
Other autoantigen specific molecular mimicry relationships
between EBNA-1 and spliceosomal antigens have been proposed
[33,34]. Existing data are consistent with a model that starts with
anti-EBNA-1 and then initially cross-reacts with anti-PPPGMIPP
(Figure 4), but this progression, which is in preference to the anti-
PPPGMRPP of anti-Sm, has not yet been formally tested.
This study is limited by the availability of stored serum samples
and presumptions based upon the timing of the samples collected.
Many of our critical observations are made from the 34 patients
who are documented to begin with a single initial autoantibody
specificity prior to clinical classification with lupus. Since our
conclusions concerning the initiation of lupus autoimmunity are
derived from a minority of the subjects considered, the potential
distorting influence of ascertainment bias should be weighed.
Furthermore, the use of standardized solid phase assays and
Western blots allows for some variation in detection sensitivity and
specificity between autoantigens and techniques, which is made
more problematic by making many of these measurements as close
to the limit of detection as is possible. We are reassured that the
solid phase assay results presented herein closely resemble the
proportions found in previous studies focusing on Western blot
results in a different cohort [14]. We are also reassured by the high
concordance between Western blot and the commercial solid
phase bead assay results. The concordance of anti-60 kD Ro, anti-
La, anti-Sm and anti-nRNP between the two assays was 90%,
80%, 85% and 84%, respectively, with none of the differences
making a material difference to the interpretations offered;
specifically, the rate and order of appearance of the autoantibodies
tested by ELISA did not differ from the solid phase autoantibody
data presented.
Despite the limitations and uncertainties that these constraints
and considerations place on the interpretation of the results, the
data are at a minimum consistent with a number of broad
interpretations and, in the context of other work, contribute to a
Figure 4. Potential mechanism for development of autoanti-
b o d i e st h r o u g hac o m m o ne n v i r o n m e n t a le t i o l o g y .While
potential structural mimics are known with EBNA-1 for Ro, Sm B, Sm D,
nRNP A, nRNP C and nRNP 70 K, no such structural relationship is known
for a heteroimmune response operating to generate anti-dsDNA, anti-
chromatin or anti-ribosomal P.
doi:10.1371/journal.pone.0009599.g004
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Lupus begins as a less complicated autoimmune process, often
involving a single lupus-specific reactivity. The single specificities
that are able to initiate lupus autoimmunity include at least the
autoimmune responses against 60 kD Ro, nRNP A, dsDNA,
phospholipid, and ribosomal P. For lupus the initiating autoanto-
gens do not generally include nRNP 70 K or Sm. The data are
also consistent with anti-Ro always preceding anti-La and with
anti-nRNP A preceding anti-nRNP 70 K. Anti-dsDNA as a first
specificity precedes anti-chromatin, but later and in the presence
of other specificities in the serum anti-chromatin may precede
anti-dsDNA. All in all, these data are consistent with the possibility
that lupus autoimmunity as detected by autoantibody binding is
initiated by a single autoantibody specificity, which is also
consistent with the progression of epitope spreading in lupus
described previously [16–22] and, also, hereby becomes a
hypothesis to be further tested by future experiments.
To a limited extent these data also address the relative disease
process specificity of the initiation of lupus autoimmunity. The less
lupus-specific autoantibodies directed against rheumatoid factor or
just anti-nuclear antibodies, when also present at diagnosis in these
cases, may or may not precede lupus-specific autoantobodies. That
they do not in the majority of cases re-enforce the contention that
at its fundamental level of autoimmune initiation lupus is an
autoantigen-specific disorder and that many of the non-specific
autoantibodies arise subsequently as a consequence of lupus
immunopathogenesis.
In summary, the development of autoantibodies in some SLE
patients appears to begin with a simple autoimmune response
binding a single autoantigen. These proteins are members of a
restricted set of autoantigens known to be capable of being the
initiating target for human lupus autoimmunity. Previous work
suggests that at least some of these antibodies arise from the
anti-EBNA-1 heteroimmune response. After passing through this
autoantigenic bottleneck, the initial humoral autoimmune re-
sponse then usually diversifies, with the sequential development of
autoantibodies binding multiple specificities before clinical pre-
sentation and diagnosis. Common patterns of autoantibody
development suggest common underlying mechanisms within
these subsets. Similar initial target epitopes suggest similar origins.
Despite the impressive clinical and serologic diversity seen in SLE,
we demonstrate a relatively limited and definable set of conserved
humoral development profiles that initiate and are present before
clinical disease arises. The essential elements for some human
lupus patients would be a particular hetero-immune response (e.g.,
anti-EBNA-1) that generates heteroimmune and autotimmune
cross-reacting antibodies (e.g, EBNA-1 and 60 kD Ro). From this
small but dangerous beginning the immune response penetrates
the autoantigenic bottleneck. The initiating autoantigen (e.g,
60 kD Ro) in lupus is a sufficiently robust auto-immunogen to
sustain the expansion and increasing complexity of the autoim-
mune response culminating in this life-threatening autoimmune
disease.
Materials and Methods
Study Population and Design
Appropriate IRB approval was obtained from the Oklahoma
Medical Research Foundation, the University of Oklahoma
Health Sciences Center, the Walter Reed Army Medical Center,
and National Naval Medical Center. Use of coded, previously
collected samples waived the necessity for informed consent. The
research was conducted in compliance with the Helsinki
Declaration (version 2000).
Military rheumatologists queried computer databases of military
hospital records and other clinical records to identify individuals
with a potential SLE diagnosis (based upon the ICD-9 code 710.0).
Inclusion criteria included having been diagnosed with SLE while
serving in the United States military or reserves, satisfying any 4 of
the 11 American College of Rheumatology (ACR) SLE classifi-
cation criteria [3, 4), having at least one retrievable serum sample
that was collected before clinical SLE diagnosis and having a
sufficient amount of sera available for this study from the
Department of Defense Serum Repository (DoDSR) [14,23–26].
Cumulative clinical features and laboratory results were
collected from the chart of each identified SLE patient,
particularly the date of the first appearance of each ACR clinical
criterion. SLE diagnosis was determined by the military clinician
(CCE). Demographic information included self-reported race/
ethnicity, gender and age at disease onset, which was classified as
meeting at least one ACR clinical criterion for SLE classification
[3,4]. Once all SLE patients were identified, the Department of
Defense Serum databases were queried to identify SLE-unaffected
control individuals. Four controls were matched for each patient
based on self-reported race/ethnicity, gender, age, length of
service in the military, and number of available samples in the
repository. For this study, one matched control for each patient
was randomly selected as a control for the autoantibody assays.
Both the first and last available sample were analyzed from each
control that had more than one sample available (n=70).
Autoantibody Analyses by Bead-Based, Solid Phase
Assays
Undiluted serum samples from patients and controls were
assayed using a commercially available bead-based, solid phase
technology, the BioPlex ANA Screen
TM kit performed with the
BioPlex 2200
TM instrument (Bio-Rad, Hercules, CA) [35–38].
These assays use multiplex technology and dyed magnetic beads to
simultaneously perform measurements of 13 autoantibodies within
5 ml of an individual serum sample. This kit enabled the detection
of the antibodies against any of the following antigens: SS-A 60
(60 kD Ro), SS-A 52 (52 kD Ro), SS-B (La), SmRNP complex,
Sm, RNP 68, RNP A, centromere B, Scl-70 (topoisomerase 1), Jo-
1, chromatin, dsDNA, and ribosomal P [35–38]. Centromere B,
Jo-1, nRNP 70 K, nRNP A, Scl-70 (topoisomerase 1), and 52 kD
Ro were all recombinantly produced; dsDNA was synthesized by
polymerase chain reaction; and the remaining antigens were
affinity purified from calf thymus extract by the manufacturer.
The BioPlex 2200
TM system, a fully automated, random access
analyzer, reports semi-quantitative values from 0–8, termed the
antibody index (AI), for each autoantibody except anti-dsDNA.
The positive cut-off for each assay was established by the
manufacturer to equal 1.0 AI. For anti-dsDNA this method
performs a quantitative assay; the results of which are reported as
IU/mL with a positive threshold of 10 IU/mL. Guidelines from
the manufacturer for the use of these control cut-offs were based
upon use with control sets from a somewhat uniform, Caucasian-
based healthy control population. Based upon the demographic
nature of this cohort, including 62% African American, 10%
Hispanic, 2% Asian and only 26% of European-American
ancestry, we determine sample positivity based upon antibody
binding of $4SD above the normal mean of a cohort of 130
healthy military individuals with the same racial, age and gender
composition of our experimental lupus cohort. Internal quality
control measures are used for assays. Positive, negative and
calibrator controls were required to all measure within a standard
range. Serum Factor XIIIb levels were tested in all samples to
ensure quality control of the sera and to ensure sample integrity
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commercial assay and has been useful to determine the integrity of
the samples and to determine whether the samples have been
properly handled during long-term storage (data proprietary and
not presented). Of the 600 SLE and 199 control samples that were
tested, 67 and 5, respectively, had low Factor XIIIb errors
indicating possible degradation. These sera were dropped from
our analysis, which did not alter the interpretation of our results.
Significantly more factor XIIIb errors were found in sera from
patients than in sera from controls (OR=4.9; p,0.001); however,
no unifying characteristics were identified in the patient samples
with low factor XIIIb levels. They were not samples from the same
people, stored in the same boxes, nor collected during any specific
time frame. Factor XIIIb levels in SLE patients have not been
systematically studied to our knowledge.
Western Blot Analysis
Electrophoresis was performed on HeLa cell extracts using
12.5% polyacrylamide gels under denaturing conditions and
transferred to nitrocellulose. The nitrocellulose was then used for
Western blotting, as previously described [18,20,39]. Autoantigens
were determined to be present when two blinded observers
identified distinct bands that corresponded to the appropriate
molecular weight and to the band from the known positive control
serum used in the same assay.
Standard Autoantibody Assays by ELISAs and
Immunofluorescence
All samples were tested for autoantibodies (IgM and/or IgG)
directed against cardiolipin, C1q, and rheumatoid factor (RF), as
previously described in detail [25,26]. All samples were also tested
for anti-nucelar antibodies by immunofluorescence on a HEp-2
cell substrate (ANA). All anti-dsDNA positive samples by the
commercial bead-based, solid phase assay were also tested for anti-
dsDNA by immunofluorescence against Crithidia lucillae as
previously described [14,23].
Statistical Analyses
For the commercial assay results, the threshold for positive
binding was set by using the control sera at mean binding plus four
standard deviations. Control values for each of the 13 autoanti-
bodies were normally distributed. For each antibody, mean times
from first observed positive test to diagnosis were calculated using
all individuals who ever developed that specificity. A Student’s t-
test was used to test for differences in the time of onset of different
autoantibody specificities relative to the age at diagnosis or
meeting a clinical criterion. Categorical variables (such as ethnicity
and gender) were assessed by the chi-square statistic or Fisher’s
exact tests. Chi squares were used as appropriate to compare the
order of autoantibody appearance.
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